Loading organizations...
§ Private Profile · 750 Main St, Cambridge, Massachusetts, 02139, United States
Predicta Biosciences is a technology company.
Predicta Biosciences develops genomic diagnostic tests for blood cancers and autoimmune diseases. Its core product, GenoPredicta, offers a non-invasive genomic assay for multiple myeloma. This technology utilizes multiomic analysis from liquid biopsies, analyzing DNA and RNA from blood samples. It aims to enhance diagnosis and monitoring by providing an alternative to traditional, invasive procedures.
Founded by distinguished researchers Irene Ghobrial, Gad Getz, Romanos Sklavenitis Pistofidis, and Ken Anderson, from the Broad Institute and Dana-Farber Cancer Institute. Their insight arose from the critical need for precise, less invasive diagnostic methods, leveraging deep expertise in cancer genomics and multiple myeloma.
Predicta Biosciences’ products serve medical professionals and patients managing blood cancers and autoimmune conditions. The company’s vision is to advance diagnostic capabilities, addressing limitations in disease detection and prognosis. It aims to deliver accurate, accessible solutions, transforming disease understanding and management for improved patient care.
Predicta Biosciences has raised $28.0M across 2 funding rounds.
Predicta Biosciences has raised $28.0M in total across 2 funding rounds.
Predicta Biosciences has raised $28.0M in total across 2 funding rounds.
Predicta Biosciences's investors include Ann DeWitt, BlueStone Venture Partners, The Engine, Ulu Ventures, Binney Street Capital, BrightEdge Ventures, Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, Myeloma Solutions Fund, American Cancer Society, Mara Aspinall.
Predicta Biosciences has raised $28.0M across 2 funding rounds. Most recently, it raised $23.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $23M Series A | ANN Dewitt | BlueStone Venture Partners, The Engine, ULU Ventures, Binney Street Capital, Brightedge Ventures, Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, Myeloma Solutions Fund | Announced |
| Jul 1, 2024 | $5M Seed | ANN Dewitt | BlueStone Venture Partners, The Engine, ULU Ventures, American Cancer Society, Mara Aspinall, Time Boost Capital | Announced |
Predicta Biosciences is a precision oncology company founded in 2023 that develops diagnostic and therapeutic products using multi-omics technology and liquid biopsies for non-invasive cancer testing, primarily targeting multiple myeloma and other blood cancers.[1][2][3][4] Its flagship product, GenoPredicta, is a Laboratory Developed Test (LDT) launched in April 2025 that analyzes whole genome sequencing (WGS) from blood or bone marrow to detect genomic alterations, stratify risk, and guide personalized treatments like CAR-T and bispecific antibodies, outperforming traditional FISH assays.[1][2][3][4] The company serves oncologists, patients, and healthcare providers by solving limitations in early detection and treatment optimization for incurable blood cancers and autoimmune diseases, with $28.6M raised to date—including a $23.4M round in October 2025—and strong growth via partnerships with Dana-Farber, academic centers, and groups like HealthTree Foundation.[1][2]
Predicta Biosciences emerged in 2023 from Harvard's Blavatnik Life Lab Longwood, founded by leading academics and clinicians from Harvard Medical School, MIT, Dana-Farber Cancer Institute, and the Broad Institute, including co-founders Irene Ghobrial, MD (multiple myeloma expert) and Kenneth C. Anderson, MD (cancer genomics specialist).[1][3][4] These physician-scientists, who treat patients daily, identified gaps in non-invasive diagnostics for blood cancers like multiple myeloma, where early detection and precise therapy selection remain challenging despite advances in immunotherapies.[2][3] Early traction came from research use of GenoPredicta at Dana-Farber, leading to its commercial LDT launch in April 2025 and a pivotal $23.4M funding round in October 2025, which appointed Brian McKernan as CEO to drive scaling.[1][2]
Predicta stands out in precision oncology through these key strengths:
Predicta rides the precision oncology wave, fueled by exploding demand for non-invasive diagnostics amid CAR-T, bispecifics, and personalized immunotherapies for blood cancers, where traditional tools fail to match therapeutic precision.[2][3] Timing is ideal post-2025 LDT launch, as regulatory shifts favor WGS-based tests and multi-omics data explodes, addressing a $10B+ market gap in multiple myeloma (no cure, poor early detection).[1][2] Market forces like aging populations, rising autoimmune cases, and AI integration amplify this, positioning Predicta to influence the ecosystem by feeding its database into drug discovery, partnering with pharma, and setting standards for liquid biopsy in hematologic malignancies.[1][3]
Predicta is poised for explosive growth, scaling its CLIA lab, commercializing GenoPredicta expansions, and launching autoimmune tests with $23.4M fuel and McKernan's leadership.[2] Trends like AI-multiomics convergence and immunotherapy dominance will propel its database into a therapeutics powerhouse, potentially yielding novel targets amid pharma's scramble for blood cancer assets.[1][3] Its influence could evolve from diagnostics leader to ecosystem shaper, humanizing precision oncology for patients long underserved by outdated tools—transforming "Predicta Biosciences is a technology company" into the understatement of biotech's next decade.